Aggressive blood pressure control may fight Alzheimer's in the brain

NCT ID NCT05331144

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study investigates whether intensively lowering systolic blood pressure with FDA-approved medications can reduce the buildup of amyloid and tau proteins in the brain—hallmarks of Alzheimer's disease. The trial enrolls adults aged 60-85 with high blood pressure who are cognitively normal but at increased risk for memory decline. Participants receive either intensive blood pressure treatment or follow their usual care, and brain changes are measured using PET scans and MRI over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
antihypertensive medications (losartan and amlodipine, plus others if needed)
What this could lead to
If successful, this could show that aggressively treating high blood pressure reduces Alzheimer's disease pathology, potentially pointing to a new prevention strategy.
What could go wrong
This is a Phase 2 trial with a moderate sample size, so results may not be conclusive. Intensive blood pressure lowering also carries risks like dizziness or falls in older adults.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVELY NORMAL OLDER ADULTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.